Equity Profile

CRMD

CorMedix Inc.

Health CarePharmaceuticals$652.7M

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with serious medical conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors closely monitor.

$0.43

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market position and operational success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRMD Q2-2026 Earnings Preview

Context

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with serious medical conditions. Operating in the health care sector, its work is particularly relevant as the demand for effective treatments continues to grow amidst an aging population and increasing healthcare needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

In Q1-2026, CorMedix reported an EPS of $0.43, surpassing expectations by 24.64%. The stock reacted positively, gaining 5.73% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to enhancing operational efficiencies.
Plans to increase market penetration.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has demonstrated strong EPS performance in recent quarters, but revenue details remain unclear.

Bull Case

If CorMedix continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence.

Bear Case

Conversely, any sign of revenue stagnation or failure to meet EPS expectations could lead to significant stock declines.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.43

EPS is a key indicator of the company's profitability and performance, which investors closely monitor.

Revenue Growth

N/A

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market position and operational success.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong historical EPS performance, this figure will be critical in determining market sentiment.

What are the revenue expectations for the upcoming quarter?

Understanding revenue growth will help gauge the company's market position and operational success.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CorMedix's ability to sustain its EPS growth despite revenue uncertainties, as historical performance suggests resilience.

Supporting Evidence

CorMedix has an 88% EPS beat rate in recent quarters, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting potential for a surprise.

Key Risk

If the EPS comes in below $0.34, it could invalidate the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CorMedix can maintain its strong EPS performance amidst uncertain revenue projections.

Bull Confirmed If

An EPS of $0.43 or better would confirm the bullish sentiment.

Bear Confirmed If

An EPS below $0.34 would likely confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±22.51%

Historical Avg

±17.1%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±22.5% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (50K)P/C Ratio: 0.11Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests a potential stock increase of around 2.06%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline of approximately 11.52%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue expectations.
5Details on any new partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with serious medical conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, which investors closely monitor.

$0.43

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market position and operational success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRMD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

In Q1-2026, CorMedix reported an EPS of $0.43, surpassing expectations by 24.64%. The stock reacted positively, gaining 5.73% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to enhancing operational efficiencies.
Plans to increase market penetration.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has demonstrated strong EPS performance in recent quarters, but revenue details remain unclear.

Bull Case

If CorMedix continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence.

Bear Case

Conversely, any sign of revenue stagnation or failure to meet EPS expectations could lead to significant stock declines.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.43

EPS is a key indicator of the company's profitability and performance, which investors closely monitor.

Revenue Growth

N/A

While specific revenue estimates are not available, growth in revenue is crucial for assessing the company's market position and operational success.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong historical EPS performance, this figure will be critical in determining market sentiment.

What are the revenue expectations for the upcoming quarter?

Understanding revenue growth will help gauge the company's market position and operational success.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CorMedix's ability to sustain its EPS growth despite revenue uncertainties, as historical performance suggests resilience.

Supporting Evidence

CorMedix has an 88% EPS beat rate in recent quarters, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting potential for a surprise.

Key Risk

If the EPS comes in below $0.34, it could invalidate the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CorMedix can maintain its strong EPS performance amidst uncertain revenue projections.

Bull Confirmed If

An EPS of $0.43 or better would confirm the bullish sentiment.

Bear Confirmed If

An EPS below $0.34 would likely confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±22.51%

Historical Avg

±17.1%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±22.5% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (50K)P/C Ratio: 0.11Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests a potential stock increase of around 2.06%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline of approximately 11.52%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue expectations.
5Details on any new partnerships or collaborations.